MELBOURNE, Australia, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Executive summaryPositive Results in the Half Year to 31 December 2022

Continued here:
Global SCENESSE® demand drives increased CLINUVEL revenues, earnings

Results presented at 30th Conference on Retroviruses and Opportunistic Infections (CROI) Results presented at 30th Conference on Retroviruses and Opportunistic Infections (CROI)

Go here to see the original:
eFFECTOR Therapeutics Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID

FREMONT, CA, Feb. 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that approval to initiate the Phase II study of its Vitargus® medical device, in Australia, was received from the Australian Therapeutic Goods Administration (TGA) on February 9, 2023. Vitargus is the first biodegradable vitreous substitute to facilitate retina reattachment surgery.

Read more:
ABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus®

-- Infant Phase 2 Study Initiation Expected in the Second Quarter of 2023, with Initial Topline Safety, Tolerability and Immunogenicity Data by 2025 ---- Based on Positive Topline VAX-24 Phase 1/2 Proof-of-Concept Study Results in Adults, FDA Supported Initiation of Pediatric Program in Infants --

See more here:
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

RESEARCH TRIANGLE PARK, N.C., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™ today announced it will report fourth quarter 2022 financial results prior to the market open on Monday, March 6, 2023.

See original here:
Science 37 to Report Fourth Quarter 2022 Financial Results on March 6, 2023

SOUTH SAN FRANCISCO, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will report fourth quarter and year-end 2022 financial results on Tuesday, February 28, 2023, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 PM Pacific Time/5:00 PM Eastern Time.

More here:
Allogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023

BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced that a review of initial data from its Phase 1b chemoprotection trial of ALRN-6924 in patients with p53-mutated breast cancer showed that patients in the trial experienced severe neutropenia (Grade 4) and alopecia. The primary endpoint of the Phase 1b open-label trial, which was evaluating ALRN-6924 in patients with breast cancer receiving neoadjuvant or adjuvant treatment with docetaxel, doxorubicin, and cyclophosphamide, or “TAC” chemotherapy, was duration and incidence of severe neutropenia in cycle 1. Incidence of chemotherapy-induced alopecia (hair loss) was a secondary endpoint. Based on these findings, Aileron has decided to terminate the Phase 1b breast cancer trial and further development of ALRN-6924.

See the original post:
Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives

-Second field trial confirms Camelina tolerance to over-the-top herbicide application

Original post:
Yield10 Bioscience Announces Key Advancements in the Development of Herbicide Tolerant Camelina Supporting Large Acreage Production of Low-carbon...

Poster Session Highlights the Strong Dose-Response Relationship and the Importance of Treating Beyond 30 Treatments With NeuroStar Advanced Therapy Poster Session Highlights the Strong Dose-Response Relationship and the Importance of Treating Beyond 30 Treatments With NeuroStar Advanced Therapy

See original here:
Neuronetics Sponsors the 5th International Brain Stimulation Conference

EDMONTON, Alberta, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. ?(TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients and disruptive technologies for healthcare and cosmetic industries, announced today that it has been named as one of the top performers on the TSX Venture Exchange.

Original post:
Ceapro Inc. Recognized as a Top 50 TSX Venture Exchange Company